1 in 4 patients had their diagnosis changed to EPI after initially being diagnosed with another GI condition.10*
Consider PERTs—the standard of care for EPI treatment—as part of your comprehensive EPI management plan.2,12
Tools and resources are available to help you diagnose and manage EPI.
*EPI Uncovered is based on an online survey conducted by Harris Poll from May 17 through June 20, 2016. It included 1,001 US adults ages 18 and older who experienced at least 2 gastrointestinal issues 3 or more times in the past 3 months (“patients”), as well as 250 primary care physicians (PCPs) and 250 gastroenterologists in the US who are ages 18 years or older and licensed. Figures for patients were weighted where necessary based on age, education, gender, race/ethnicity, region, income, size of household, marital status, and likelihood to be online to bring them into line with their actual proportions in the population. Figures for PCPs and gastroenterologists were weighted on years in practice, gender, and region, where necessary, to bring them into line with their actual proportions in the population.
†Retrospective study to quantify the time between the presence of symptoms suggestive of EPI prior to initiating a PERT. To be eligible for the study, a patient must: 1) have a history of at least 1 medical claim in each year during the 5-year study period (between 2014 and 2019), 2) have at least 1 EPI diagnosis during this period, and 3) have initiated PERT in 2019. Time to PERT was based on the first occurrence of the symptom code prior to PERT prescription claim.
AGA = American Gastroenterological Association; EPI = exocrine pancreatic insufficiency; GI = gastrointestinal; PERT = pancreatic enzyme replacement therapy.
CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Please see Full Prescribing Information.
US-CREO-220154
References: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc. 2. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clin Exp Gastroenterol. 2011;4:55-73. 3. Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol. 2011;8(7):405-415. 4. Xu Y, Wu D, Zeng Y, Wang X. Pancreatic exocrine function and morphology following an episode of acute pancreatitis. Pancreas. 2012;41(6):922-927. doi:10.1097/MPA.0b013e31823d7f2d 5. Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. doi:10.2147/CEG.S168266 6. Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994;107(5):1481-1487. 7. Sandhu BS, Hackworth WA, Stevens S, Bouhaidar DS, Zfass AM, Sanyal AJ. Recurrent flares of pancreatitis predict development of exocrine insufficiency in chronic pancreatitis. Clin Gastroenterol Hepatol. 2007;5(9):1085-1091. 8. Chaudhary A, Domínguez-Muñoz JE, Layer P, Lerch MM. Pancreatic exocrine insufficiency as a complication of gastrointestinal surgery and the impact of pancreatic enzyme replacement therapy. Dig Dis. 2020;38(1):53-68. doi:10.1159/000501675 9. Hart PA, Conwell DL. Diagnosis of exocrine pancreatic insufficiency. Curr Treat Options Gastroenterol. 2015;13(3):347-353. 10. Data on file. North Chicago, IL: AbbVie Inc. Harris Poll. EPI Awareness Survey. American Gastroenterological Association; 2016. 11. Data on file. SHS data. Patients initiating in 2019-H1 and 2019-H2; 2018. 12. Smith RC, Smith SF, Wilson J, et al; Working Party of the Australasian Pancreatic Club. Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology. 2016;16(2):164-180. doi:10.1016/j.pan.2015.12.006